GENOME ANNOUNCEMENT
===================

Cystic fibrosis (CF) patients are subjected to intensive antibiotic therapy, and it is evident that this crucially affects the process of bacterial adaptation to the CF lung environment ([@B1], [@B2]). To further investigate the effects of antimicrobial chemotherapy on the adaptation of *Pseudomonas aeruginosa* to the CF lung, we sequenced the genomes of four strains of the *P. aeruginosa* B3 clone type isolated from consecutive sputum samples from a patient with long-term chronic *P. aeruginosa* infection undergoing 3 months of combination chemotherapy with oral ciprofloxacin and inhaled colistin due to recurrent isolation of *P. aeruginosa*. The sputum samples were collected and the strains were isolated as part of a longitudinal study where the first and subsequent samples were stored from the beginning of 2005 until July 2009 ([@B1]). The first sample was collected before chemotherapy was initiated and is represented by *P. aeruginosa* B3-1811, a mucoid isolate that was determined at the clinic to be colistin and ciprofloxacin sensitive. A sputum sample collected 2 months after the initiation of therapy contained *P. aeruginosa* with two different bacterial colony morphologies: a mucoid and colistin-sensitive strain (*P. aeruginosa* B3-208) and a nonmucoid and colistin-resistant strain (*P. aeruginosa* B3-20M). The last strain (*P. aeruginosa* B3-CFI), also colistin resistant, was isolated from a sputum sample obtained at the end of the 3-month treatment regime. Genomic DNA from the B3-1811, B3-208, B3-20M, and B3-CFI strains was prepared and sequenced as described previously ([@B3]) to generate 3,077,857, 2,445,795, 3,026,144, and 3,881,715 75-bp reads, respectively.

Using Velvet version 1.0.16, the reads were assembled into the draft genomes of strain B3-1811, with 6,657,892 bp, 285 contigs, and an N~50~ of 82,268 bp; strain B3-208, with 6,701,506 bp, 344 contigs, and an N~50~ of 66,611 bp; strain B3-20M, with 6,704,349 bp, 278 contigs, and an N~50~ of 77,595 bp; and strain B3-CFI, with 6,727,794 bp, 252 contigs, and an N~50~ of 87,472 bp. The optimal assembly settings were estimated using VelvetOptimiser (the Victorian Bioinformatics Consortium \[VBC\], Monash University; see <http://www.vicbioinformatics.com/software.velvetoptimiser.shtml>), with only contigs of ≥500 bp retained, and the assembly was assisted by initial mapping of the reads against the reference genome sequences of *P. aeruginosa* PAO1 ([@B4]) using the Velvet Columbus module.

A comparison of the genomes using MUMmer3 ([@B5]) revealed the four isolates to be closely related, sharing at least 99.6% of their genomic contents. The sequences of the four strains reported here will help to elucidate the genetic diversity that exists within clonal populations of *P. aeruginosa* sampled from a single CF patient and how the genetic composition can change quickly due to new selection pressures, such as antibiotic therapy.

Nucleotide sequence accession numbers. {#h1}
--------------------------------------

These genome sequences have been deposited in EMBL under the following accession no. (BioProject no.): [CBMP010000001](http://www.ncbi.nlm.nih.gov/nuccore?term=CBMP010000001) to [CBMP010000341](http://www.ncbi.nlm.nih.gov/nuccore?term=CBMP010000341) (PRJEB4309) for strain B3-1811, [CBMT010000001](http://www.ncbi.nlm.nih.gov/nuccore?term=CBMT010000001) to [CBMT010000418](http://www.ncbi.nlm.nih.gov/nuccore?term=CBMT010000418) (PRJEB4310) for strain B3-208, [CBMU010000001](http://www.ncbi.nlm.nih.gov/nuccore?term=CBMU010000001) to [CBMU010000338](http://www.ncbi.nlm.nih.gov/nuccore?term=CBMU010000338) (PRJEB4311) for strain B3-20M, and [CBMS010000001](http://www.ncbi.nlm.nih.gov/nuccore?term=CBMS010000001) to [CBMS010000314](http://www.ncbi.nlm.nih.gov/nuccore?term=CBMS010000314) (PRJEB4312) for strain B3-CFI.
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